Psychiatr. praxi. 2025;26(1):10-14 | DOI: 10.36290/psy.2025.002

Treatment of pharmacoresistant states in psychiatry - Part 1: Treatment-resistant schizophrenia

prof. MUDr. Eva Češková, CSc.
Psychiatrická klinika LF MU a FN Brno
Odd. psychiatrie FN Ostrava a LF Ostravské univerzity

The paper is focused on pharmacotherapy of treatment-resistant schizophrenia and exclusion of pseudoresistance. The treatment options including switch, augmentation and combination of antipsychotics are described. Finally, perspective substances are briefly mentioned.

Keywords: treatment-resistant schizophrenia, pseudoresistance, switch of antipsychotics, clozapine, augmentation, combination of antipsychotics, precision psychiatry.

Accepted: March 27, 2025; Published: April 10, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Treatment of pharmacoresistant states in psychiatry - Part 1: Treatment-resistant schizophrenia. Psychiatr. praxi. 2025;26(1):10-14. doi: 10.36290/psy.2025.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 10.4.2026

    References

    1. Vasiliu O, Budeanu B, Cătănescu MȘ. The new horizon of antipsychotics beyond the classic dopaminergic hypothesis - the case of the xanomeline-trospium combination: A systematic review. Pharmaceuticals (Basel). 2024;17(5):610. Go to original source... Go to PubMed...
    2. Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin. 1997;14(1):1-20. Go to original source... Go to PubMed...
    3. Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019; 80(2):18com12123. Go to original source... Go to PubMed...
    4. Falkai P, Wobrock T, Lieberman J, et al. WFSBP Task Force on treatment guidelines for schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3):132-91. Go to original source... Go to PubMed...
    5. Hadzi Boskovic D, Liang S, Parab P, et al. Real-world evidence of aripiprazole tablets with sensor: Treatment patterns and impacts on psychiatric healthcare resource utilization. Clinicoecon Outcomes Res. 2023; 15:487-498. Go to original source... Go to PubMed...
    6. Šilhán P, Hýža M, Ambroš S, et al. Terapeutické monitorování psychofarmak 1: základní principy. Psychiatrie. 2023; 27(2):81-89.
    7. Hýža M, Šilhán P, Škrda D, et al. Terapeutické monitorování psychofarmak 3: využití u jednotlivých lékových skupin. Psychiatrie. 2024;28(1):27-36.
    8. Češková E, Valášková I, Pindurová E, et al. Farmakogenetické testy a jejich současné využití v psychiatrické praxi. Čes a slov Psychiatr. 2022;118(6):237-239.
    9. Goto S, Terao T, Tomita M, et al. Aripiprazole may be free from tachyphylaxis: preliminary findings. Psychiatry Clin Neurosci. 2012;66(2):160-2. Go to original source... Go to PubMed...
    10. Huhn M, Nikolakopoulou A, Schneider T, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Focus (Am Psychiatr Publ). 2020;18(4):443-455. Go to original source... Go to PubMed...
    11. Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208-224. Go to original source... Go to PubMed...
    12. Dong S, Schneider-Thoma J, Bighelli I. A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2024; 274(4):917-928. Go to original source... Go to PubMed...
    13. Vinnakota C, Hudson MR, Jones NC, et al. Potential roles for the GluN2D NMDA receptor subunit in schizophrenia. Int J Mol Sci. 2023; 24(14):11835. Go to original source... Go to PubMed...
    14. Gurrera RJ, Gearin PF, Love J, et al. Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis. Acta Psychiatr Scand. 2022; 145(5):423-441. Go to original source... Go to PubMed...
    15. Lichnovský O, Ustohal L. Vysazení klozapinu z důvodu neutropenie a možnosti jeho opětovného nasazení do medikace. Psychiatrie. 2022;26(4):167-171.
    16. Chengappa KNR, Cotes RO. Clozapine's high incidence of ileus and pneumonia demand better clinical strategies-how do we get there? Am J Psychiatry. 2024;181(10):851-853. Go to original source... Go to PubMed...
    17. Kahn RS, Winter van Rossum I, Leucht S, et al. OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018; 5(10):797-807. Go to original source... Go to PubMed...
    18. Mayerová M, Horská K, Ustohal L. Klozapin: moderní antipsychotikum s dlouhou tradicí. První vydání. Praha: Galén. 2021: 202 s.
    19. Morozov P, Bekker R, Bykov Y. Cariprazine's potential in improving social dysfunction in patients with schizophrenia: A perspective. Front Psychiatry. 2022;13:868751. Go to original source... Go to PubMed...
    20. Ceskova E. Pharmacological strategies for the management of comorbid depression and schizophrenia. Expert Opin Pharmacother. 2020; 21(4):459-465. Go to original source... Go to PubMed...
    21. Cheuk NKW, Tse W, Tsui HKH, et al. A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia. Schizophr Res. 2024;268:205-222. Go to original source... Go to PubMed...
    22. Votava M, Podgorna G, Nguyen T, et al. Switchapp - aplikace pro zobrazení doporučeného postupu při změně léčby antipsychotiky a antidepresivy. Čes a slov Psychiat. 2021;117(4):185-189.
    23. Galling B, Vernon JA, Pagsberg AK, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018;137(3):187-20. Go to original source... Go to PubMed...
    24. Xiu M, Zhao L, Sun Q, et al. Efficacy of low-dose olanzapine in combination with sertraline on negative symptoms and psychosocial functioning in schizophrenia: A randomized controlled trial. Curr Neuropharmacol. 2024; 22(8):1406-1413. Go to original source... Go to PubMed...
    25. Shi H, Xu J, Lang X, et al. Comparison of efficacy and safety between low-dose ziprasidone in combination with sertraline and ziprasidone monotherapy for treatment-resistant patients with acute exacerbation schizophrenia: A randomized controlle trial. Front. Pharmacol. 2022;13:863588. Go to original source... Go to PubMed...
    26. Arsenault-Mehta K, Hochman-Bérard M, Johnson A, et al. Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review. Neuropsychopharmacol Rep. 2024; 44(1):2-16. Go to original source... Go to PubMed...
    27. Brand BA, Willemse EJM, Hamers IMH, et al. Evidence-based recommendations for the pharmacological treatment of women with schizophrenia spectrum disorders. Curr Psychiatry Rep. 2023; 25(11):723-733. Go to original source... Go to PubMed...
    28. Fond G, Mallet J, Urbach M, et al. Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs. BMJ Ment Health. 2023;26(1):e300771. Go to original source... Go to PubMed...
    29. Messina A, Concerto C, Rodolico A, et al. Is it time for a paradigm shift in the treatment of schizophrenia? The use of inflammation-reducing and neuroprotective drugs-A review. Brain Sci. 2023;13(6):957. Go to original source... Go to PubMed...
    30. Galling B, Roldán A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16(1):77-89. Go to original source... Go to PubMed...
    31. Oloyede E, Dima A, Taylor D, et al. Clozapine augmentation with long-acting antipsychotic injections: A case series and systematic review. Acta Psychiatr Scand. 2023;148(6):538-552. Go to original source... Go to PubMed...
    32. Nováková M, Hammer T, Nováková E, et al. Možnost ovlivnění duševního zdraví u pacientů s farmakorezistentní schizofrenií - augmentace klozapinu dlouhodobě působícími parenterálními antipsychotiky: série případů. Čes. slov. Farm. 2023;72(6):276-286. Go to original source...
    33. Arnautovska U, Kesby JP, Korman N, et al. Biopsychology of physical activity in people with schizophrenia: An integrative perspective on barriers and intervention strategies. Neuropsychiatr Dis Treat. 2022;18:2917-2926. Go to original source... Go to PubMed...
    34. Komatsu Y, Takehara M, Hart X, et al. Advancements in non-dopaminergic treatments for schizophrenia: A systematic review of pipeline developments. Pharmacopsychiatry. 2024; 57(5):221-231. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.